GR Defect in Sputum Cells in COPD

Withdrawn

• Conditions: Chronic Obstructive Pulmonary Disease (COPD)

• Registration Number: NCT00159276
• Lead Sponsor: Imperial College London

Brief Summary

To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-09-08
• Study First Submitted QC: 2005-09-08
• Study First Posted: 2005-09-12
• Study Start: 2005-12
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-03
• Last Update Posted: 2024-04-04

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers.
• Written informed consent

Exclusion Criteria

• Current upper respiratory tract infections
• Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
• Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital; 🇬🇧 London, United Kingdom